Citations

Clear

214 citation(s) found for "Mukherjee, M".

Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability
Mukherjee, Sovanlal , Antony, Ajith , Trivedi, Kamaxi H. , Karbhari, Aashna , Bhinder, Khurram Khaliq , Truty, Mark, Johnson, Matthew P. , Goenka, Ajit H. , Patnam, Nandakumar G. , Chari, Suresh T , Goenka, Ajit Harishkumar , Zarrintan, Armin , Fletcher, Joel G. , Truty, Mark J. , Chari, Suresh T.

Mayo Clinic

Gut | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: gutjnl-2025-337266

10.1136/gutjnl-2025-337266 | PMID 42049489 Get It

Background Failure of conventional imaging to detect pancreatic ductal adenocarcinoma (PDA) at its visually occult pre-diagnostic stage is a primary barrier to improving its otherwise poor rate of survival. Objective To develop and validate the Radiomics-based Early Detection MODel (REDMOD), an AI framework to identify subvisual radiomic signatures of pre-diagnostic PDA on standard-of-care CT. Designs REDMOD was trained on a multi-institutional cohort (n=969; 156 pre-diagnostic, 813 control) and tested on an independent set (n=493; 63 pre-diagnostic, 430 control), simulating a low prevalence (~1:6) early detection paradigm. The fully automated framework couples AI-driven segmentation with a heterogeneous ensemble architecture trained on a 40-feature radiomic signature derived from Synthetic Minority Over-sampling Technique (SMOTE)-balanced data. A tunable Youden Index-optimised classification threshold enables performance calibration without retraining. Validation included direct comparison with radiologists, longitudinal test–retest analysis and external specificity validation across two independent cohorts (n=539 and n=80). Results On an independent test set (n=493), REDMOD identified occult PDA (AUC 0.82; 73.0% sensitivity) at a median 475-day lead time. This represented nearly twofold higher sensitivity than radiologists (38.9%; p<0.001), which grew to nearly threefold (68.0% vs 23.0%) at >24 months lead time. REDMOD showed strong longitudinal stability (90–92% concordance) and generalisable specificity across multi-institutional (81.3%; n=539) and public (87.5%; n=80) datasets. Mechanistic analyses confirmed predictive power derived principally from multi-scale wavelet-filtered textural features (90% of selected signature), which outperformed unfiltered features (AUC 0.82 vs 0.74; p=0.007) in capturing subvisual architectural disruptions. Conclusions REDMOD is an automated, mechanistically grounded, longitudinally stable, externally validated AI that surpasses radiologists for PDA detection at its visually occult pre-diagnostic stage. These attributes position it for prospective validation in high-risk cohorts, a necessary step towards shifting the paradigm from late-stage symptomatic diagnosis to proactive pre-clinical interception.
Abstract LB228: DPYSL2 mediates extracellular vesicle-driven reprogramming of the glioblastoma tumor microenvironment
Russo, Marissa, Norton, Emily, Wang, Weiwei, Mukherjee, Shreyartha, Wickland, Daniel P. , Lam, TuKiet, Guerrero-Cázares, Hugo, Russo, Marissa , Norton, Emily S. , TuKiet, L., Guerrero‐Cazares, Hugo

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB228-LB228

10.1158/1538-7445.am2026-lb228 Get It

Abstract The purpose of this study was to identify glioblastoma (GBM) proteins that contribute to the hijacking of the tumor microenvironment through extracellular vesicles (EVs). GBM is the most aggressive primary brain tumor in adults. It presents significant challenges due to its universal recurrence and limited survival rates, exacerbated when its located proximal to the lateral ventricles (LV). The cellular subpopulation of brain tumor-initiating cells (BTICs) plays a pivotal role in tumor initiation and invasiveness, interacting with the microenvironment, particularly the cellular components in the subventricular zone (SVZ) in the LV. We employed an integrated multi-omic strategy combining cell-specific proteomics of EV cargo and whole-cell transcriptomics of EV-treated neural progenitor cells (NPCs) to define mechanisms by which BTICs remodel the tumor microenvironment. Using the TurboID cell-specific protein labeling system, we identified a previously unrecognized repertoire of BTIC-derived proteins selectively packaged into EVs. Among these, DPYSL2 (CRMP2) emerged as a prominent EV cargo as it is implicated in cancer cell migration and invasion. Functionally, exposure of human NPCs to BTIC-derived EVs significantly increased NPC proliferation and migratory capacity in vitro, findings that were recapitulated in vivo following intracranial and intranasal delivery of GBM-derived EVs. To define the molecular basis of these phenotypic changes, we performed RNA sequencing of NPCs following EV treatment. Bioinformatic integration, including ontogenic and pathway enrichment analyses, revealed robust activation of oncogenic signaling pathways, notably JAK/STAT, mTOR, and WNT, accompanied by upregulation of downstream effector genes. Importantly, integrative proteomic-transcriptomic analyses identified DPYSL2 as a mechanistic link between EV cargo and NPC transcriptional reprogramming. Prior studies demonstrate that DPYSL2 can interact with JAK kinases, promoting STAT3 activation and transcription of genes such as Vimentin (VIM) and CALCA, consistent with the transcriptomic changes observed in EV-treated NPCs. Overall, we have identified DPYSL2 as a novel regulator of tumor microenvironment hijacking mediated by extracellular vesicles. This multi-omic approach is the first use of cell-specific proteomics to study extracellular vesicles and the first time pairing this method to identify upstream regulators of transcriptomic changes in neural progenitor cells. Collectively, these findings establish a direct molecular connection between BTIC-derived EV proteins and functional reprogramming of neural progenitor cells, providing mechanistic insight into how glioblastoma exploits developmental programs to promote tumor progression. Citation Format: Marissa Russo, Emily Norton, Weiwei Wang, Shreyartha Mukherjee, Daniel Wickland, TuKiet Lam, Hugo Guerrero-Cazares. DPYSL2 mediates extracellular vesicle-driven reprogramming of the glioblastoma tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB228.
Abstract LB205: Dissociation between prediagnostic imaging phenotype and tumor biology defines the early detection challenge in pancreatic ductal adenocarcinoma
Bhinder, Khurram Khaliq , Mukherjee, Sovanlal , Jadoon, Ahmed Khan , Feng, Ziding, Goenka, Ajit H. , Zarrintan, Armin , Ammirabile, Angela , Ziding, Feng, Chari, Suresh T.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB205-LB205

10.1158/1538-7445.am2026-lb205 Get It

Abstract Background: Early detection is the most potent strategy to improve survival in PDA, but its success hinges on an unresolved question: does radiologically invisible disease represent biologically early or indolent disease, or established malignancy beneath the threshold of detection? We leveraged prediagnostic CTs—incidental scans obtained 3-36 months prior to diagnosis without a focal mass—to define the relationship between imaging phenotype and tumor biology. Methods: From a multi-institutional pool of 5,046 biopsy-confirmed PDAs, we assembled a cohort of 346 prediagnostic CTs, which were independently evaluated by three radiologists using a standardized protocol. Based on majority vote, CTs were dichotomized into imaging-occult (IO) (normal pancreas) and imaging-apparent (IA) (abnormal pancreas with indirect signs such as focal atrophy, duct dilatation, etc.) groups. Tumor size and metastases (M) at diagnosis, and overall survival (OS) were compared using multivariable linear (size), logistic (M1), and Cox proportional hazards (OS) models, adjusting for lead time to diagnosis, age, sex, diabetes, CA 19-9, and surgical resection status, to isolate the independent biological relevance of the imaging phenotype. Results: IO phenotype was seen in 150 patients (mean age 66.7±11.2; 37.3% females) while 196 had IA phenotype (mean age 69.9±10.6; 49.5% females). Median lead time was 396 days (range: 90-1088) with the IA group being enriched in 3-12-month lead time (57.7% vs 33.3%; p&lt;0.001). Both groups had comparable diabetes rates (IA 33.2% vs IO 32.7%; p=1.0), median CA 19-9 (IA 193 vs IO 322 U/mL; p=0.41), and surgical resection (IA 38.3% vs IO 38.0%; p = 1.0). While unadjusted mean tumor size at diagnosis was larger in IA group (3.8 cm vs 3.2 cm), there was no difference after adjusting for clinical factors (-7.1% difference; 95% CI: -17.2, 4.2; p=0.21). Metastases were also comparable (M rate: IA 22.4% vs IO 27.3%; adjusted OR 0.97; 95% CI: 0.50, 1.88; p=0.93). Adjusted Cox models demonstrated equivalent OS (median: 18.7 vs 17.6 months; HR 1.06; p=0.66), which persisted even when stratified by surgical status (HR 1.07; 95% CI: 0.83, 1.38; p=0.61). Even in the critical 3-12 months lead time (n=163), OS remained equivalent (HR 0.89; p=0.62), and groups did not differ in either tumor size (-6.4%; 95% CI: -22.4, 12.9; p=0.49) or metastases (OR 0.48; 95% CI 0.14, 1.59; p=0.23). Conclusions: A normal-appearing pancreas on prediagnostic imaging is common yet signifies neither early nor indolent disease—it harbors PDA biologically equivalent to the imaging-apparent pancreatic phenotype. Because the disease at this stage lies beyond human perceptual capacity, AI augmentation represents the only potential path to realizing the survival benefit of early detection. Citation Format: Khurram Khaliq Bhinder, Sovanlal Mukherjee, Armin Zarrintan, Angela Ammirabile, Ahmed Khan Jadoon, Ziding Feng, Suresh T. Chari, Ajit H. Goenka. Dissociation between prediagnostic imaging phenotype and tumor biology defines the early detection challenge in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB205.
Metabolomics of Right Ventricular Function in Pulmonary Hypertension
Chacon-Barahona, Jonathan , Chung, Samuel J. , Garry, Jonah , Frantz, Robert P. , Hassoun, Paul M. , Mathai, Stephen C. , Simpson, Catherine E. , Beck, Gerald, Hill, Nicholas S. , MUKHERJEE, MONICA, Jacob, Miriam , Park, M H, Finet, J Emanuel, Farha, Samar , Grünig, Gabriele , Kwon, Deborah, Comhair, Suzy , Erzurum, Serpil, Barnard, John, Jellis, Christine , Racanelli, Alexandra Christin, Krumsiek, Jan , hemnes, anna, Horn, Evelyn, Group, on behalf of the PVDOMICS Study, Beck, Gerald J. , Garry, Jonah D , Hassoun, Paul M , Mathai, Stephen C , Simpson, Catherine E , Beck, Gerald J , Hill, Nicholas S , Leopold, Jane A , Waxman, Aaron B. , Rosenzweig, Erika B , Borlaug, Barry A , Mukherjee, Monica , Vanderpool, Rebecca R , Jacob, Miriam , Mehra, Reena , Park, Margaret M , Finet, J Emanuel , Kwon, Deborah H , Comhair, Suzy , Erzurum, Serpil C , Barnard, John , Hu, Bo , Jellis, Christine L , Krumsiek, Jan , Brittain, Evan L , Hemnes, Anna , Horn, Evelyn M , Frantz, Robert P , Chacon-Barahona, Jonathan , Chung, Samuel J. , Rischard, Franz , Leopold, Jane A. , Rosenzweig, Erika B. , Borlaug, Barry A. , Mukherjee, Monica , Vanderpool, Rebecca , Mehra, Reena , Finet, J. Emanuel , Erzurum, Serpil C. , Racanelli, Alexandra C. , Hemnes, Anna R. , Gro, on behalf of the PVDOMICS Study

Mayo Clinic

Circulation Research | April 15, 2026 | Volume: 138 | Issue: 11 | Pages: No page available

10.1161/circresaha.125.327342 | PMID 41983297 Get It

BACKGROUND: The metabolic mechanisms underlying right ventricular (RV) dysfunction are poorly understood, particularly outside of group 1 pulmonary hypertension (PH). We aimed to identify metabolites and pathways associated with RV systolic function and explored whether associations differed by pulmonary vascular resistance, PH group 1 status, and sex. METHODS: We analyzed data from the multicenter PVDOMICS (Pulmonary Vascular Disease Phenomics) cohort. RV systolic function metrics included fractional area change (echo), global longitudinal strain (echo), and ejection fraction (cardiac magnetic resonance). We used linear regression adjusted for age, sex, body mass index, and PH group to assess associations between metabolites and RV function. Pathway enrichment analyses were used to identify pathways significantly associated with RV function. Interaction terms were assessed to determine whether metabolite associations were modified by pulmonary vascular resistance, group 1 PH status, or sex. Least absolute shrinkage and selection operator regression was used to develop metabolite-based scores for RV function, and prognostic performance was assessed. RESULTS: There were 979 participants with plasma metabolomics and RV function data. Linear regression identified 170 metabolites that were significantly associated with all 3 RV metrics. Androgenic steroid, gamma-glutamyl amino acid, polyamine, vitamin A, fatty acid, and sterol pathways are most strongly associated with RV systolic function. Two metabolites interacted with group 1 PH status, and 6 interacted with pulmonary vascular resistance. Four androgenic steroids are associated more strongly with RV systolic function in women compared with men. Metabolite-based scores were prognostically equivalent to RV systolic function metrics and less accurate than REVEAL Lite 2 scores. CONCLUSIONS: We provide a blueprint of metabolites and metabolic pathways associated with RV systolic function across the spectrum of PH. Novel links to vitamin A and glutathione metabolites were observed. We detected few metabolites that associated with RV systolic function differentially by group 1 PH status or degree of pulmonary vascular resistance elevation. Androgenic steroids may associate more strongly with RV systolic function in women compared with men.
NCCN Guidelines® Insights: Distress Management, Version 1.2026
Fann, Jesse R., Vanderlan, Jessica, Brewer, Benjamin W. , Corbett, Cheyenne , Keller, Jennifer A. , Lahijani, Sheila , Niazi, Shehzad K. , Riba, Michelle B., Braun, IIana, Breitbart, William S., Channa, Yamna, Farabelli, Jill P., Fleishman, Stewart B., Garcia, Sofia F. , Greenberg, Donna B., Handzo, George , Horyna, Amy, Hutchinson, Sean Z., Johns, Shelley A. , Cava, Shannon La, Martin, Sara , Mukherjee, Debraj, Pailler, Megan E. , Parnes, Francine, Rocha-Cadman, Xiomara, Scher, Eli D. , Schuster, Jessica, Thompson, Lora M.A., Usher, A., Valentine, Alan , Darlow, Susan, Mukherjee, Debraj , Mukherjee, Debraj , Garcia, Sofia F , Fann, Jesse R. , Andersen, Barbara L. , Atreya, Chloe Evelyn , Breitbart, William S., Greenberg, Donna, Huang, Chao‐Hui , Leeper, Heather , Rao, Vinay P. , Rocha‐Cadman, Xiomara , Thompson, Lora M.A., Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2026.0018 | PMID 41956112 Get It

These NCCN Guidelines for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer. They are intended to assist oncology teams to identify patients who require referral to psychosocial resources and to give oncology teams guidance on interventions for patients with significant distress. These guidelines also provide guidance for social workers, certified chaplains, and mental health professionals by describing treatments and interventions for various psychosocial problems as they relate to patients with cancer. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding standards of care for distress management in patients with cancer and implementation of these standards, including application of evidence-based care delivery models, such as the collaborative care model.
Risk Factors for Postoperative Cerebrospinal Fluid Leak Following Endoscopic Transsphenoidal Surgery for Craniopharyngioma: A Multicenter Cohort Study with a Contemporary Surgeon Practice Survey
Celda, María Peris, Karsy, Michael, Evans, James J, Kim, Albert H, Kim, W, Bergsneider, Marvin , Pacione, Donato , Gardner, Paul A. , Mukherjee, Raj, Liu, Connor J. , Cheok, Stephanie , Zwagerman, Nathan T. , Christenson, Charles, Blackburn, Spiros, Kshettry, Varun R, Wu, Kyle C, Prevedello, Daniel, Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Zada, Gabriel, Benjamin, Carolina , Catalino, Michael Paul, Mamelak, Adam N, Furlan, André Beer, Zenonos, Georgios, Mendoza, Michelle Magana, Little, Andrew S, Gompel, Jamie J., Karsy, Michael , Palit, Sandhya R. , Shinya, Yuki , Karsy, Michael , Evans, James J., Chicoine, Michael , Kim, Albert H , Patel, Bhuvic , Kim, Won Bae , Gardner, Paul, Mukherjee, Debraj , Liu, C P, Blackburn, Spiros , Kshettry, Varun R. , Rennert, Robert C , Couldwell, William T. , Morshed, Ramin A. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Zada, Gabriel , BENJAMIN, CAROLINA, Mamelak, Adam N. , Zenonos, Georgios A. , Little, Andrew S. , Gompel, Jamie J. Van

Mayo Clinic

No container title available | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9285619/v1 | PMID 41994110 Get It

Abstract Purpose: This multicenter, multi-surgeon retrospective study aimed to identify risk factors for postoperative cerebrospinal fluid (CSF) leak following endonasal resection of craniopharyngioma, while evaluating the "perception gap" through a surgeon survey. Methods: A retrospective review was conducted on 416 patients who underwent endoscopic transsphenoidal surgery (ETS) for craniopharyngioma from 20 institutions. Factors were compared between patients with and without postoperative CSF leak, and between Early (2007-2015) and Late (2016-2025) Epochs. Complementing the clinical data, a survey of 19 neurosurgeons captured expert perspectives on risk stratification and management strategies. Results: Overall postoperative CSF leak rate was 13.5% (56/416 patients). Univariate analysis identified predominantly cystic tumors (34% vs. 21%, p = 0.034)and intraoperative lumbar drain (LD) use ( p < 0.028) as associated with postoperative CSF leak. BMI ( p = 0.587), prior surgery ( p = 0.576), and tumor size ( p = 0.363) were not significant. In the multivariable analysis, LD use was associated with a higher postoperative CSF leak rate (OR 1.91, 95% CI 1.06–3.46; p = 0.030). Between Epochs, nasoseptal flap (NSF) utilization increased from 70.7% to 87.6% ( p <0.001). NSF was protective (OR 0.28, 95% CI 0.07–0.92; p = 0.037) in the Early Epoch; no factors were significant in the Late Epoch. The surgeons’ survey identified prior surgery and intraoperative high flow leaks as primary risks; however, their LD protocols diverged from clinical data. Conclusion: Despite increased use of NSF, CSF leak persists. The study highlights a significant divergence between expert perception and clinical data regarding lumbar drains.
Abstract 643: The Sean Karl Cohort: An international single-cell RNAseq study of paired patient Ewing sarcoma specimens.
Pannucci, Abbe , Mukherjee, Elina , Daley, Jessica, Ganapathi, Shireen Sita, Surrey, Lea F. , Gutstein, Lauren, Azar, Patrick, Neyaz, Azfar, John, Ivy, Tanaka, Yutaro , Butaney, Byron, Janeway, Katherine A. , Taroni, Jaclyln, Davis, Jade, Laetsch, Theodore W. , Mody, Rajen , Henon, Clémence , Grünewald, Thomas G., Lawlor, Elizabeth R. , Cruz, Filemon S. Dela, Grohar, Patrick J. , Pavisic, Jovana , Hawkins, Ally, Ganapathi, Shireen S. , Boguslawski, Elissa A. , Azar, Patrick, Stockfisch, Emily , Neyaz, Azfar , John, Ivy , Picarsic, Jennifer , Gillani, Riaz , Crompton, Brian D. , Reed, Damon R. , Shlien, Adam , Grünewald, Thomas G. P. , Cruz, Filemon S. Dela , Cillo, Anthony Richard , Bailey, Kelly M.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 643-643

10.1158/1538-7445.am2026-643 Get It

Abstract Introduction: Ewing sarcoma (EwS) is a FET::ETS family member-driven primary bone cancer demonstrating vast heterogeneity. Between a patient’s primary diagnosis and disease progression, tumor cell state adaptation, microenvironment changes, and the landscape of evolving therapeutic vulnerabilities remain poorly understood. To address these gaps, the Sean Karl Cohort was established in 2025 to conduct the largest single-cell transcriptomic analysis of retrospective paired tumor samples from patients with EwS. Here, we present data from the five analytic teams, and through shared SOPs now expand this cohort to Europe. Methods: Common sample processing SOPs were established to isolate cells from FFPE material from paired patient EwS samples. Single-cell (sc) RNAseq was generated using the GEM-X Flex Gene Expression protocol (10x Genomics). Alex’s Lemonade Stand Foundation (ALSF) Data Lab established a common data processing and integration pipeline with an EwS-specific cell annotation workflow to create a harmonized dataset for downstream analyses. Analytic teams were created to define tumor cell subpopulations and their therapeutic vulnerabilities and to characterize the tumor microenvironment. Data: We demonstrate the feasibility of generating high-quality scRNAseq profiles from retrospective FFPE-preserved EwS tumors. To date, 116 samples have yielded ∼800,000 cells. Integrated analysis reveals reproducible EwS tumor cell states shared across patients with regulatory network analyses nominating candidate therapeutic vulnerabilities. The scale of this international cohort enables saturation analysis for rare cell populations. Paired and longitudinal samples further allow correlation of emergent cell states with therapy resistance and metastatic progression. For example, immune-focused analyses show increases in T cell and macrophage populations in post-therapy samples. A novel, standardized EwS-specific cell annotation workflow has been developed to harmonize analyses and findings. These data will be openly shared with the community through the ALSF Single-cell Pediatric Cancer Atlas Portal. Conclusion: Large-scale international collaborative sample sharing, standardized processing pipelines, and harmonized EwS-specific annotations now enable deep single-cell analyses to characterize tumor heterogeneity in this rare pediatric and adolescent cancer. An in vivo expansion of the Sean Karl Cohort is underway to assess conservation of EwS tumor cell states and regulatory vulnerabilities identified in human tumors pre- and post-therapy in preclinical models, further supporting translation of these findings toward therapeutic strategies. Citation Format: Abbe Pannucci, Elina Mukherjee, Jessica D. Daley, Shireen Sita Ganapathi, Elissa Boguslawski, Lea Surrey, Lauren Gutstein, Patrick Azar, Emily Stockfisch, Azfar Neyaz, Ivy John, Jennifer Picarsic, Yutaro Tanaka, Byron Butaney, Riaz Gillani, Brian D. Crompton, Katherine A. Janeway, Jaclyln Taroni, Jessica Davis, Damon Reed, Adam Shlien, Theodore W. Laetsch, Rajen Mody, Clémence Henon, Thomas G. Grünewald, Elizabeth R. Lawlor, Filemon Dela Cruz, Patrick J. Grohar, Jovana Pavisic, Ally Hawkins, Anthony R. Cillo, Kelly M. Bailey. The Sean Karl Cohort: An international single-cell RNAseq study of paired patient Ewing sarcoma specimens [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 643.
Modeling cis -regulatory variation in human brain enhancers across a large Parkinson’s Disease cohort
Sigalova, Olga , Pančíková, Alexandra , Man, Julie De , Theunis, Koen , Hulselmans, Gert , Konstantakos, Vasileios , Stuyven, Bram , Brabandere, Anton De, Geurts, Jarne , Mikorska, Antonina , Mukherjee, Shinjini , Vandereyken, Katy, Davie, Kristofer , Mahieu, Lukas, Adler, Charles H., Beach, Thomas G., Serrano, Geidy E., Voet, Thierry , Aerts, Stein , Sigalova, Olga M , De Man, Julie , Hulselmans, Gert J , De Brabandere, Anton , Abouelasrar Salama, Sara , Vandereyken, Katy , Davie, Kristofer , Mahieu, Lukas , Adler, C H , Beach, Thomas G , Serrano, Geidy E , Voet, Thierry , Demeulemeester, Jonas , Aerts, Stein , Adler, Charles H. , Beach, Thomas G. , Serrano, Geidy E.

Mayo Clinic

No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.15.711881 | PMID 41889906 Get It

Abstract Genome-wide association studies (GWAS) have linked more than a hundred non-coding genomic loci to Parkinson’s disease (PD) risk. Deciphering their functional impact on gene regulation requires cell type-aware modeling approaches to assess the effects of sequence variation on enhancer function and target gene expression. To address this challenge, we generated a comprehensive matched dataset from 190 human donors (115 controls and 75 PD), comprising long-read whole-genome sequencing alongside single nucleus multiome atlases (snATAC-seq and snRNA-seq for 3.1 and 1.1 million nuclei respectively) of the anterior cingulate cortex and substantia nigra. By integrating chromatin accessibility quantitative trait loci (caQTL), DNA methylation QTL (meQTL), and allele-specific chromatin accessibility (ASCA), we identified 53,841 high-confidence cis -acting genetic variants that modulate cell type-specific enhancer accessibility in one or both brain regions. We further demonstrate that sequence-to-function models can accurately predict the impact of these variants directly from the genomic sequence. Novel explainability approaches allowed stratifying these variants according to their regulatory function, with the majority disrupting specific transcription factor binding sites in a cell type specific manner. Integrating these “enhancer variants” (EV) with eQTL mapping and gene locus modeling linked a subset of EVs to their target genes. Finally, we applied these models to prioritize regulatory variants at known PD GWAS loci, bypassing statistical limitations in rare disease-relevant populations like dopaminergic neurons. All together, we establish a unique resource and new sequence modeling strategies to interpret functional non-coding variation in the human brain.